Subscribe to NRx Newsletter

Highlight Articles

Featured image
NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not […]

Continue Reading
Featured image
NRx Pharmaceuticals’ Interim CEO Presentation at 21st Annual Needham Virtual Healthcare Conference

Presented on Thursday, April 14 The 21st Annual Needham Virtual Healthcare Conference took place on April 11-14, 2022 and featured fireside chats and presentations from leading public and private companies […]

Continue Reading
3PLAccelerated RecoveryACTIV-3ACTIV-3bActive3bAcute Respiratory Distress SyndromeAcute Respiratory FailureAdaptive Platform Trial DesignAnthony S Fauci MDARDSAviptadilAvitpadilBARDABig Rock PartnersBioConnect Virtual ConferenceBiotechBipolar DepressionBNP ParibasBoosterBreakthrough Therapy DesignationBRilifeBRILife®BTDCAHCardinal HealthCEOCFOCH HealthChaim HurvitzCheddar NewsClinical TrialsClosing BellCOID-19Commercial ForumlationCompassionate CareconferenceCovidCovid-19COVID-19 SurvivalCOVID-AIVCovid19Critical COVID-19CromosCytokine IL-6Cytokine StormCytokinesData Safety Monitoring BoardDeltaDelta VariantDenk PharmaDisease preventionDisease prevention & Control SummitDr YoDr. Sami SaidDr. Shmuel YitzhakiDry-powder InhalerDSMBEAPEkaterine TikaradzeEmegency Use AuthorizationEmergency UseEmergency Use Authorizationerectile dysfunctionEUAEuropean QPExpanded AccessFast TrackFDAFDA EmeFDA Emergency Use AuthorizationFDA Module 3Federal Right to Try ActFinancial ResultsFox BusinessGeorgiaGeorgia Society of PhysiciansGeorgian Ministry of HealthGILDGileadGovernment of LuxembourgH.C. Wainwright & Co.HC WainwrightHC Wainwright Annual Global Investment ConferenceHC Wainwright Global Investment ConferenceHigh Flow NasalHoustonHouston MethodistHouston Methodist JC Walkter Jr Transplant CenterI-Spyi24 NewsICUIIBRIL-6 CytokineInhaled AviptadilIQVIQVIAIra StrassbergiSpyIsraelIsrael Institute of Biological ResearchIV ZYESAMI®J. Georges YoussefJ&JJihad Georges YoussefJihad Georges Youssef MDJihad Geroges YoussefJournal of Infectious Diseases and TreatmentlawsuitLuxembourgLuxembourg Ministry of the EconomyMannkindMDMental HealthMNKDMolnupiravirNanoPassNASDAQNation of GeorgiaNational Institutes of HealthNDA ZyesamiNeedhamNehpron PharmaceuticalsNephronNephron PharmaceuticalsNIAIDNIHNRXNRx BriLife COVID VaccineNRx Business UpdateNRx EarningsNRx PharmaceuticalsNRX-100NRX-100/101NRX-101NRX101NRXPOmicronOrphan Drug DesignationPandemicPeptidesPharmacovigilancePhase 2presentationPrivate PlacementProf Jonathan JavittProf Jonathan Javitt MD MPHPsychiatric CarePTSDQ1 EarningsQ2 EarningsQ3 Finaincial ResultsQP AuditorQP DeclarationQuantum Leap HealthcareRemdesivirRespiratory Distress RatioRespiratory FailureRichard G Lugar Center for Public HealthRichard Luger CenterRIght to TryRightToTryRLF-100RLF-100_002Robert BesthofRTTSami SaidSar-CoV-2Sars-CoV-2Sever COVID-19Suicidal DepressionSuicidalityTechnosphereTESICOUCIUkraineUS Food and Drug AdministrationUSFDAVaccineVaccine TrialVaccine TrialsVasoactive Intestinal PeptideVekluryVIPVirologywebcastZYESAMIZYESAMI®ZYESAMI™ZYESAMI™ INDZysamiZYSAMI®ZYSAMI® (aviptadil)